Telix kicks off OPTIMAL-e TLX597-Tx Phase 2 in mHSPC catalyst
Jul 15, 2026, 4:23 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Phase 2 dosing milestone plus adaptive Dosing approach could improve the addressable early-stage prostate cancer market, potentially supporting multiple near-term upside catalysts if data show deeper PSA responses and manageable safety. Historical analogs show phase 2 trial initiations and dosing milestones can re-rate radiopharma names on favorable safety/efficacy signals.
AI summary
What happened, with direct paths to the underlying reporting
Telix announced the first dosing of TLX597-Tx in OPTIMAL-e, a Phase 2 trial for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital. The study tests adaptive dosing with ADT and an ARPI, guided by PSMA-PET and PSA. If successful, the approach could deepen responses and extend disease control, potentially expanding TLX597-Tx use in earlier disease settings.
First patients dosed in OPTIMAL-e Phase 2 TLX597-Tx trial. Metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney.
OPTIMAL-e uses adaptive dosing with ADT and ARPI. PSA and PSMA-PET monitor response to guide treatment.
TLX597-Tx is Telix's next-gen PSMA radioligand therapy designed for earlier-stage disease. Aims to improve efficacy and quality of life.
OPTIMAL-PSMA recently completed enrollment; OPTIMAL-e builds on progress and broadens TLX PSMA portfolio.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
FDA approved Telix's Gozellix for prostate cancer PET testing. Gozellix has a longer shelf life than existing products. Shares of TLX increased 6% after FDA announcement. Telix sh…
